Supplementary Figure S2 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Tobias Keßler; Daniel Schrimpf; Laura Doerner; Ling Hai; Leon D. Kaulen; Jakob Ito; Martin J. van den Bent; Martin Taphoorn; Alba A. Brandes; Ahmed Idbaïh; Julien Dômont; Paul M. Clément; Mario Campone; Martin Bendszus; Andreas von Deimling; Felix Sahm; Michael Platten; Wolfgang Wick; Antje Wick

doi:10.1158/1078-0432.27033694.v1

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplementary Figure 2: Overall (A) and progression-free (B) survival in the EORTC-26101 clinical study (n = 596) and EORTC-26101 biomarker cohort (n = 380).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keßler et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db64358752281b https://doi.org/10.1158/1078-0432.27033694.v1

View at Publisher

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplementary Figure 2: Overall (A) and progression-free (B) survival in the EORTC-26101 clinical study (n = 596) and EORTC-26101 biomarker cohort (n = 380).

Supplementary Figure S2 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading